Business Context and Reporting Period
Adial Pharmaceuticals, Inc. filed this Form 8-K on October 2, 2026, reporting an event from October 1, 2026, concerning its 2026 Annual Meeting of Stockholders.
Key Financial Information
This filing reports no financial results, cash flow, debt, liquidity, or other financial metrics.
Material Event
The Company reconvened its annual meeting on October 1 to consider Proposals 3, 4, 5, and 6. Because it had not received Nasdaq approval of its Initial Listing Application, it further adjourned the meeting. The polls on these proposals remain open. The filing states that no changes were made to the proposals.
Outlook, Risks, and Other Matters
The meeting is scheduled to reconvene on October 15, 2026, at 8:30 a.m. Eastern Time, at the Company’s offices in Charlottesville, Virginia. The record date remains August 17, 2026. Stockholders who already submitted proxies on Proposals 3–6 need not act unless they want to change their votes. The timing of the vote remains dependent on Nasdaq approval.
Important Facts to Verify
- Whether Nasdaq grants approval of the Initial Listing Application before the reconvened meeting.
- The outcome of the votes on Proposals 3, 4, 5, and 6.
- The proposal details in the Company’s definitive proxy statement filed August 24, 2026.